SUMO1 Antikörper

Produktnummer ABIN3026266

Der Maus Monoklonal anti-SUMO1 Antikörper (Klon S1MT-2) (ABIN3026266) detektiert spezifisch SUMO1 in WB, IF und IHC (p). Dieser Antikörper reagiert spezifisch mit Proben aus Human und Ratte.

Kurzübersicht für SUMO1 Antikörper (ABIN3026266)

Target: SUMO1 (Small Ubiquitin Related Modifier Protein 1 (SUMO1))

Reaktivität: Human, Ratte

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser SUMO1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Güteklasse: Carrier-free

Klon: S1MT-2

Produktdetails anti-SUMO1 Antikörper

Verwendungszweck: SUMO1 Antibody (azide and preservative free)

Aufreinigung: Protein G affinity chromatography

Immunogen: Recombinant human protein was used as the immunogen for this SUMO1 antibody.

Isotyp: IgG1, kappa

Anwendungsinformationen

Applikationshinweise: Titering of the SUMO1 antibody may be required for optimal performance.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the SUMO1 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Details zu SUMO1

Target: SUMO1 (Small Ubiquitin Related Modifier Protein 1 (SUMO1))

Andere Bezeichnung: SUMO1

Hintergrund: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability.

Pathways: M Phase, Positive Regulation of Endopeptidase Activity, Protein targeting to Nucleus, Ubiquitin Proteasome Pathway